TomoTherapy to Introduce TomoDirect™ at ESTRO, ASTRO Annual Meetings

MADISON, Wis.--(BUSINESS WIRE)--TomoTherapy Incorporated (NASDAQ: TOMO) today announced that it will introduce the TomoDirect™ discrete-angle delivery mode1 for the TomoTherapy® Hi·Art® treatment system at two upcoming radiation oncology conferences. This innovative new technology allows Hi·Art system users to quickly plan and deliver advanced TomoTherapySM radiation treatments with a series of linear beam paths, rather than the existing helical path. With TomoDirect, clinicians can choose several discrete angles and the optimal modulation level required for delivery, based on specific patient therapy goals. TomoDirect will be unveiled at the annual meetings of the European Society for Therapeutic Radiology and Oncology (ESTRO) in Gothenburg, Sweden, Sept. 14-18, 2008, and the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, Mass., Sept. 21-25, 2008.

“We are excited about TomoDirect because it will greatly increase the overall flexibility and efficiency of the Hi·Art treatment system,” said Fred Robertson, CEO of TomoTherapy. “Along with helical TomoTherapy delivery, TomoDirect will enhance our customers’ revenue-generating opportunities, and strengthen their ability to deliver the highest quality radiation therapy to the broadest patient population.”

souirce: Business Wire